Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Needham

Tesla Stock Upgraded By Needham As More Bears Change Course

Bulls and bears may not agree on where Tesla’s stock will go in the coming years, but one such bear recently changed its stance on the company’s shares.

InsideEVs

Tesla's Giga Shanghai Goes Full Throttle, Fisker Gets Wall Street's Love, Ford Issues Ultimatum To Dealers, Biden's Charging Infrastructure Thrust: Week's Biggest EV Stories

Electric vehicle stocks closed the week ending Sept. 17 on a mixed note, as investors reacted to the macroeconomic uncertainty that dragged the broader market lower, analysts’ actions, and a positive policy move. Now, here are the key events that happened in the EV space during the week:

Benzinga

Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session

Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) jumped 35.4% to $13.54 after gaining 11% on Thursday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Vauxhall Motors stay top and extend unbeaten run after Congleton Town victory

Vauxhall Motors remain top of the North West Counties Premier League division following a 2-0 win over Congleton Town

Liverpool Echo

Top Financial Media Stories Thursday, September 15: US Railway Companies, Unions Reach Tentative Agreement, Tesla To Wind Down Stores In China's Flashy Malls, Netflix Could Face Legal Action Over South Korean Crime Drama And More..

US Railway Companies, Unions Reach Tentative Agreement Averting Catastrophic Strike

Benzinga

Tesla Vs. Fisker Vs. Rivian Vs. Lucid: Analyst Weighs In On EV Makers As Adoption Shifts To Top Gear

The adoption of electric vehicles is progressing at a faster-than-expected rate, given automakers’ thrust to EV transitioning, governments’ mandates to ban ICE vehicles, and huge capital infusion into the space sector, an analyst at Needham said in a note.

Benzinga

DocuSign Shares Gain On 'Better-Than-Feared' Earnings Beat: 5 Analysts Chime In

Shares of DocuSign Inc. (NASDAQ: DOCU) jumped more than 17% in Friday’s pre-market after the company reported better-than-expected quarterly results and raised its full-year billings outlook. Here's what analysts had to say:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

nCino Analysts Cheer Q2 Beat Amid Uncertain Macros

nCino, Inc (NASDAQ:NCNO) reported Q2 revenues of $99.6 million, up 50% Y/Y, beating the consensus. Adjusted EPS loss of $(0.04) surpassed the consensus. KeyBanc analyst Josh Beck maintained an Overweight and lowered the price target from $40 to $35. nCino reported solid results similar to the adjusted prior-quarter result driven by a potent mix of go-lives,…

Benzinga

Analysts Cheer Workday's Better Than Feared Q2 Amid Macro Concerns

Workday, Inc (NASDAQ:WDAY) clocked 21.9% revenue growth in Q2 to $1.54 billion, which beat average analyst estimates. The subscription revenues of $1.37 billion were up 22.8%. Workday reported EPS of $0.83, which beat average analyst estimates. Workday reported solid 2Q23 results highlighted with an uncertain macro backdrop pressuring sales much less than feared, Needham analyst…

Benzinga

Analysts Continue To See Upside In Salesforce Post Q2 Beat Despite Challenging Macros

Salesforce, Inc (NYSE:CRM) clocked 22% revenue growth to $7.72 billion in Q2, beating consensus. The EPS of $1.19 topped the consensus. The board approved a buyback of up to $10 billion. The Q3 and FY guidance were below the consensus. Mizuho analyst Gregg Moskowitz reiterated a Buy and cut the price target from $245 to $235.…

Benzinga

EBay "Thesis Not Changing" Analysts Say After Strong Guidance, Mixed Earnings

Analysts are sizing up the second-quarter financial report from marketplace and auction company eBay Inc (NASDAQ: EBAY), which reported results Wednesday after market close. The eBay Analysts: Needham analyst Anna Andreeva had a Hold rating and no price target.

Benzinga

Harmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat

Harmony Biosciences crushed expectations Tuesday, citing a growing number of narcolepsy patients on its drug, and the biotech stock surged.

Investors Business Daily

6 Amazon Analysts React To Q2 Earnings Report: 'Our Top '22 FANG Stock'

Amazon.com, Inc. (NASDAQ: AMZN) shares traded higher by 11.5% on Friday after the company reported impressive second-quarter numbers in a difficult macroeconomic climate.

Benzinga

Enterprise Software Firms Like Coursera, Five9, Teladoc Health And More Will 'Bake Looming Macro Slowdown Into Guidance,' Cautions This Analyst

Needham analyst Scott Berg shared 2Q earnings for its Enterprise Software universe kick-off this week with seven companies reporting, namely, 2U, Inc (NASDAQ: TWOU) (

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

8 Netflix Analysts React To Q2 Earnings Beat, Subscriber Guidance, Ad-Supported Tier

Netflix, Inc. (NASDAQ: NFLX) shares gained 7.1% on Wednesday after the company reported better-than-expected subscriber losses in the second quarter and detailed plans to launch a new, low-cost, ad-supported subscription tier.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022

Upgrades

Benzinga

Needham Retains Conviction On DoorDash Despite Amazon's Collaboration With Rival Just Eat Takeaway.com

Needham analyst Bernie McTernan believes DoorDash, Inc (NYSE: DASH) can leverage its leadership position in restaurant delivery to become one of the leading, horizontal, on-demand, last-mile fulfillment providers in North America.

Benzinga

Read Why Needham Reiterated Buy On fuboTV Despite Slashing Its Price Target By 67%

Needham analyst Laura Martin saw fuboTV Inc (NYSE: FUBO) as an inexpensive way for public investors to participate in the U.S.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Needham Slashes Revenue, Earnings Projections, Price Targets of Majority Semiconductor Stocks: Key Takeaways

Needham analyst N. Quinn Bolton saw a slowdown in demand across most end markets coupled with several quarters of inventory purge is likely to significantly decrease semiconductor sales in C2H22 and 2023 from original base case estimates.

Benzinga

Needham Maintains Buy Rating for CarGurus: Here's What You Need To Know

Needham has decided to maintain its Buy rating of CarGurus (NASDAQ:CARG) and lower its price target from $40.00 to $32.00. Shares of CarGurus are trading up 0.42% over the last 24 hours, at $22.52 per share. A move to $32.00 would account for a 42.13% increase from the current share…

Benzinga

Here's Why Accolade Shares Are Trading Higher Today

Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ:ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as the company beat management's initial outlook for FY23 revenue and adjusted EBITDA. While early in the selling season, ACCD won more new business in 1QF23 than…

Benzinga

TikTok's Smaller US Rival Files For IPO

Short video app Triller Inc has confidentially filed for an initial public offering with the U.S. SEC. Recently, Triller terminated its merger with video advertising software provider SeaChange International, Inc (NASDAQ:SEAC) when it shared plans to pursue an IPO with a potential listing under the ticker symbol "ILLR" by September. Also Read: Triller Merging With SeaChange International: What Investors Should…

Benzinga

Why Did Needham Lift Price Target For Trevi?

Yesterday Trevi Therapeutics Inc's (NASDAQ:TRVI) Phase 2b/3 trial (PRISM) evaluating Haduvio (nalbuphine ER) for prurigo nodularis (PN) successfully met the key primary and secondary endpoints. Needham writes that Haduvio had a quick onset of action, reaching stat sig at 6 weeks with efficacy that had yet to plateau at the wk-14 readout. Trevi…

Benzinga

Analysts Still Believe Verrica's Ycanth Is Approvable Despite FDA Response Letter

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) held a Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of Ycanth (VP-102) for molluscum contagiosum. HC Wainwright says VP-102 was approvable, and at the time of the Complete Response Letter (CRL), Verrica had already engaged a potential alternate solution supplier. It reiterates…

Benzinga

Here's Why Needham Continues To See 105% Upside To Avalara Post Its Analyst Day

Needham analyst Scott Berg attended Avalara, Inc's (NYSE: AVLR) virtual analyst day, in which the company highlighted new products and provided intermediate-term financial targets that beat expectations.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations